Investing.com - SAB Biotherapeutics reported on Tuesday third quarter earnings that missed analysts' forecasts and revenue that was inline with expectations.
SAB Biotherapeutics announced earnings per share of $-0.160 on revenue of $6.85M. Analysts polled by Investing.com anticipated EPS of $-0.143 on revenue of $6.85M.
SAB Biotherapeutics shares are down 14.97% from the beginning of the year and are trading at $1.025 , down-from-52-week-high.
SAB Biotherapeutics shares lost 18.00% in intra-day trade the report.
SAB Biotherapeutics follows other major Healthcare sector earnings this month
SAB Biotherapeutics's report follows an earnings beat by J&J on Tuesday, October 18, 2022, who reported EPS of $2.55 on revenue of $23.79B, compared to forecasts EPS of $2.48 on revenue of $23.36B.
Eli Lilly had beat expectations on Tuesday, November 1, 2022 with third quarter EPS of $1.98 on revenue of $6.94B, compared to forecast for EPS of $1.91 on revenue of $6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar